A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. Some patients will take both imlunestrant and another treatment to suppress their ovarian function. Some will take it without ovarian suppression. Researchers will compare the effects in breast cancer cells to those of another medicine called tamoxifen. All patients in this group will be premenopausal women who have a type of early breast cancer called estrogen receptor-positive, HER2-negative. The

Trial Details

NCT ID
NCT07287098
Phase
PHASE2
Sponsor
Eli Lilly and Company
Status
RECRUITING
Cancer Type
ER/PR Positive (Hormone Receptor Positive) Breast Cancer
Interventions
  • Imlunestrant
  • Goserelin
  • Tamoxifen 20 mg
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Chandler, Arizona, United States|33.30616,-111.84125
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Los Angeles, California, United States|34.05223,-118.24368
  • Santa Monica, California, United States|34.01949,-118.49138

Key Eligibility Criteria

  • Have histologically confirmed Stage I to III Estrogen Receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) invasive b…
  • Be willing and able to provide pre- and on-treatment tumor samples.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Be able to swallow capsules or tablets.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →